Review



p foxm1 thr600 cst 14655 wb  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    Cell Signaling Technology Inc p foxm1 thr600 cst 14655 wb
    P Foxm1 Thr600 Cst 14655 Wb, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 41 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p foxm1 thr600 cst 14655 wb/product/Cell Signaling Technology Inc
    Average 93 stars, based on 41 article reviews
    p foxm1 thr600 cst 14655 wb - by Bioz Stars, 2026-02
    93/100 stars

    Images



    Similar Products

    p foxm1 thr600 cst 14655 wb  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc p foxm1 thr600 cst 14655 wb
    P Foxm1 Thr600 Cst 14655 Wb, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p foxm1 thr600 cst 14655 wb/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    p foxm1 thr600 cst 14655 wb - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    p foxm1 thr600  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc p foxm1 thr600
    RT-qPCR primers
    P Foxm1 Thr600, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p foxm1 thr600/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    p foxm1 thr600 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    p foxm1  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc p foxm1
    RT-qPCR primers
    P Foxm1, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/p foxm1/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    p foxm1 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    anti aurora a p t288 aurora b p t232 aurora c p t198  (Cell Signaling Technology Inc)
    93
    Cell Signaling Technology Inc anti aurora a p t288 aurora b p t232 aurora c p t198
    RT-qPCR primers
    Anti Aurora A P T288 Aurora B P T232 Aurora C P T198, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti aurora a p t288 aurora b p t232 aurora c p t198/product/Cell Signaling Technology Inc
    Average 93 stars, based on 1 article reviews
    anti aurora a p t288 aurora b p t232 aurora c p t198 - by Bioz Stars, 2026-02
    93/100 stars
    		  Buy from Supplier
    anti p foxm1 thr600  (Cell Signaling Technology Inc)
    94
    Cell Signaling Technology Inc anti p foxm1 thr600
    RT-qPCR primers
    Anti P Foxm1 Thr600, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti p foxm1 thr600/product/Cell Signaling Technology Inc
    Average 94 stars, based on 1 article reviews
    anti p foxm1 thr600 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    RT-qPCR primers

    Journal: Journal of Ovarian Research

    Article Title: NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells

    doi: 10.1186/s13048-024-01421-4

    Figure Lengend Snippet: RT-qPCR primers

    Article Snippet: Primary antibodies included anti- FOXM1 (Cell Signaling Technology, CST, Danvers, MA, USA) (CST #5436, 1:1,000), p-FOXM1 (Thr600) (CST #14655, 1:1,000–1:2,000), AURKB (Abcam, Waltham, MA, USA, #2254, 1:1,000), CCNB1 (CST #4138, 1:1,000–1:2,000), CDC25B (CST #9525, 1:1,000–1:2000), PLK1 (CST #4513, 1:1,000) FOXA1 (CST #53528, 1:1,000–1:2,000)), FOXK2 (CST #12008, 1:1,000), FOXO3a (CST #12829, 1:10,000), cleaved PARP (cl-PARP) (CST #5625, 1:1,000), ubiquitin (CST #14049, 1:20,000). alpha-tubulin (CST #2144, 1:5,000), β-actin (Santa Cruz Biotechnology, Dallas, TX, USA, # 47778, 1:10,000), and Lamin B1 (CST #12586, 1:1,000).

    Techniques: Sequencing

    Potency and efficacy of FOXM1 inhibitors in HGSOC cell lines a

    Journal: Journal of Ovarian Research

    Article Title: NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells

    doi: 10.1186/s13048-024-01421-4

    Figure Lengend Snippet: Potency and efficacy of FOXM1 inhibitors in HGSOC cell lines a

    Article Snippet: Primary antibodies included anti- FOXM1 (Cell Signaling Technology, CST, Danvers, MA, USA) (CST #5436, 1:1,000), p-FOXM1 (Thr600) (CST #14655, 1:1,000–1:2,000), AURKB (Abcam, Waltham, MA, USA, #2254, 1:1,000), CCNB1 (CST #4138, 1:1,000–1:2,000), CDC25B (CST #9525, 1:1,000–1:2000), PLK1 (CST #4513, 1:1,000) FOXA1 (CST #53528, 1:1,000–1:2,000)), FOXK2 (CST #12008, 1:1,000), FOXO3a (CST #12829, 1:10,000), cleaved PARP (cl-PARP) (CST #5625, 1:1,000), ubiquitin (CST #14049, 1:20,000). alpha-tubulin (CST #2144, 1:5,000), β-actin (Santa Cruz Biotechnology, Dallas, TX, USA, # 47778, 1:10,000), and Lamin B1 (CST #12586, 1:1,000).

    Techniques:

    Selectivity of FOXM1 inhibitors in HGSOC cells vs. FTE cells a

    Journal: Journal of Ovarian Research

    Article Title: NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells

    doi: 10.1186/s13048-024-01421-4

    Figure Lengend Snippet: Selectivity of FOXM1 inhibitors in HGSOC cells vs. FTE cells a

    Article Snippet: Primary antibodies included anti- FOXM1 (Cell Signaling Technology, CST, Danvers, MA, USA) (CST #5436, 1:1,000), p-FOXM1 (Thr600) (CST #14655, 1:1,000–1:2,000), AURKB (Abcam, Waltham, MA, USA, #2254, 1:1,000), CCNB1 (CST #4138, 1:1,000–1:2,000), CDC25B (CST #9525, 1:1,000–1:2000), PLK1 (CST #4513, 1:1,000) FOXA1 (CST #53528, 1:1,000–1:2,000)), FOXK2 (CST #12008, 1:1,000), FOXO3a (CST #12829, 1:10,000), cleaved PARP (cl-PARP) (CST #5625, 1:1,000), ubiquitin (CST #14049, 1:20,000). alpha-tubulin (CST #2144, 1:5,000), β-actin (Santa Cruz Biotechnology, Dallas, TX, USA, # 47778, 1:10,000), and Lamin B1 (CST #12586, 1:1,000).

    Techniques:

    Protein expression and NB compound dose response in HGSOC and FTE cells. A Western blot analyses of FOXM1, FOXM1-P (P-Threonine 600), CCNB1, FOXA1, FOXK2, and FOXO3a expression in CAOV3 (HGSOC), OVCAR4 (HGSOC), and FT282-C11 (immortalized FTE cells). β-actin staining is a shown as a protein loading control. B-C Dose–response curves of CAOV3 (red), OVCAR4 (blue), and FT282-C11 (yellow) cells treated with B NB-73 or C NB-115 for 72 h. Cell viability was analyzed by CyQuant assay. Three independent trials were performed with three technical replicates per trial. Values represent mean ± SEM. Curves were created using nonlinear regression with least squares (ordinary) fit in GraphPad Prism. IC50 values are indicated below the graphs

    Journal: Journal of Ovarian Research

    Article Title: NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells

    doi: 10.1186/s13048-024-01421-4

    Figure Lengend Snippet: Protein expression and NB compound dose response in HGSOC and FTE cells. A Western blot analyses of FOXM1, FOXM1-P (P-Threonine 600), CCNB1, FOXA1, FOXK2, and FOXO3a expression in CAOV3 (HGSOC), OVCAR4 (HGSOC), and FT282-C11 (immortalized FTE cells). β-actin staining is a shown as a protein loading control. B-C Dose–response curves of CAOV3 (red), OVCAR4 (blue), and FT282-C11 (yellow) cells treated with B NB-73 or C NB-115 for 72 h. Cell viability was analyzed by CyQuant assay. Three independent trials were performed with three technical replicates per trial. Values represent mean ± SEM. Curves were created using nonlinear regression with least squares (ordinary) fit in GraphPad Prism. IC50 values are indicated below the graphs

    Article Snippet: Primary antibodies included anti- FOXM1 (Cell Signaling Technology, CST, Danvers, MA, USA) (CST #5436, 1:1,000), p-FOXM1 (Thr600) (CST #14655, 1:1,000–1:2,000), AURKB (Abcam, Waltham, MA, USA, #2254, 1:1,000), CCNB1 (CST #4138, 1:1,000–1:2,000), CDC25B (CST #9525, 1:1,000–1:2000), PLK1 (CST #4513, 1:1,000) FOXA1 (CST #53528, 1:1,000–1:2,000)), FOXK2 (CST #12008, 1:1,000), FOXO3a (CST #12829, 1:10,000), cleaved PARP (cl-PARP) (CST #5625, 1:1,000), ubiquitin (CST #14049, 1:20,000). alpha-tubulin (CST #2144, 1:5,000), β-actin (Santa Cruz Biotechnology, Dallas, TX, USA, # 47778, 1:10,000), and Lamin B1 (CST #12586, 1:1,000).

    Techniques: Expressing, Western Blot, Staining, Control, CyQUANT Assay

    NB compound treatment suppresses FOXM1 and FOXM1-P expression in HGSOC cells. A Western blot analysis of FOXM1, FOXM1-P, and β-actin (loading control) expression in CAOV3 cells treated with the indicated concentrations of NB-73 or NB-115 for 48 h. Numerical values below the images indicate protein expression normalized by β-actin, and red numbers indicate reduced expression relative to DMSO control. B Quantified western blot data from panel A , with data from three biological replicates plotted. Two-way ANOVA with Dunnett’s multiple comparisons test, error bars indicate mean ± SD. C-D As in panels A - B , but in OVCAR4 cells treated for 72 h. E Western blot analysis of FOXM1, FOXM1-P, Lamin B1 (nuclear isolation control), α-tubulin (cytoplasm isolation control), and β-actin (overall loading control) expression in cytoplasmic and nuclear protein fractions from CAOV3 cells treated with the indicated concentrations of NB-73 and NB-115 for 48 h. Numerical values below the images indicate protein expression normalized to β-actin and red numbers indicate reduced expression relative to the DMSO control. F as in E , except in OVCAR4 cells treated for 72 h

    Journal: Journal of Ovarian Research

    Article Title: NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells

    doi: 10.1186/s13048-024-01421-4

    Figure Lengend Snippet: NB compound treatment suppresses FOXM1 and FOXM1-P expression in HGSOC cells. A Western blot analysis of FOXM1, FOXM1-P, and β-actin (loading control) expression in CAOV3 cells treated with the indicated concentrations of NB-73 or NB-115 for 48 h. Numerical values below the images indicate protein expression normalized by β-actin, and red numbers indicate reduced expression relative to DMSO control. B Quantified western blot data from panel A , with data from three biological replicates plotted. Two-way ANOVA with Dunnett’s multiple comparisons test, error bars indicate mean ± SD. C-D As in panels A - B , but in OVCAR4 cells treated for 72 h. E Western blot analysis of FOXM1, FOXM1-P, Lamin B1 (nuclear isolation control), α-tubulin (cytoplasm isolation control), and β-actin (overall loading control) expression in cytoplasmic and nuclear protein fractions from CAOV3 cells treated with the indicated concentrations of NB-73 and NB-115 for 48 h. Numerical values below the images indicate protein expression normalized to β-actin and red numbers indicate reduced expression relative to the DMSO control. F as in E , except in OVCAR4 cells treated for 72 h

    Article Snippet: Primary antibodies included anti- FOXM1 (Cell Signaling Technology, CST, Danvers, MA, USA) (CST #5436, 1:1,000), p-FOXM1 (Thr600) (CST #14655, 1:1,000–1:2,000), AURKB (Abcam, Waltham, MA, USA, #2254, 1:1,000), CCNB1 (CST #4138, 1:1,000–1:2,000), CDC25B (CST #9525, 1:1,000–1:2000), PLK1 (CST #4513, 1:1,000) FOXA1 (CST #53528, 1:1,000–1:2,000)), FOXK2 (CST #12008, 1:1,000), FOXO3a (CST #12829, 1:10,000), cleaved PARP (cl-PARP) (CST #5625, 1:1,000), ubiquitin (CST #14049, 1:20,000). alpha-tubulin (CST #2144, 1:5,000), β-actin (Santa Cruz Biotechnology, Dallas, TX, USA, # 47778, 1:10,000), and Lamin B1 (CST #12586, 1:1,000).

    Techniques: Expressing, Western Blot, Control, Isolation

    NB compound treatment suppresses FOXM1 target protein and gene expression in HGSOC cells. A Western blot analysis of FOXM1 targets and β-actin expression in CAOV3 cells treated with the indicated concentrations of NB-73 or NB-115 for 48 h. Numerical values below the images indicate protein expression normalized by β-actin and red numbers indicate reduced expression relative to DMSO control. B Quantified western blot data from panel A , data from three biological replicates are plotted. Two-way ANOVA with Dunnett’s multiple comparisons test, error bars indicate mean ± SD. C-D As in panels A - B , but in OVCAR4 cells treated for 72 h. E RT-qPCR analysis of FOXM1 target gene expression in CAOV3 cells treated with the indicated concentration of NB-73 or NB-115 for 24 h. Line indicates median, two-way ANOVA with Tukey’s multiple comparison test. F As in panel E , except in OVCAR4 cells treated for 72 h

    Journal: Journal of Ovarian Research

    Article Title: NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells

    doi: 10.1186/s13048-024-01421-4

    Figure Lengend Snippet: NB compound treatment suppresses FOXM1 target protein and gene expression in HGSOC cells. A Western blot analysis of FOXM1 targets and β-actin expression in CAOV3 cells treated with the indicated concentrations of NB-73 or NB-115 for 48 h. Numerical values below the images indicate protein expression normalized by β-actin and red numbers indicate reduced expression relative to DMSO control. B Quantified western blot data from panel A , data from three biological replicates are plotted. Two-way ANOVA with Dunnett’s multiple comparisons test, error bars indicate mean ± SD. C-D As in panels A - B , but in OVCAR4 cells treated for 72 h. E RT-qPCR analysis of FOXM1 target gene expression in CAOV3 cells treated with the indicated concentration of NB-73 or NB-115 for 24 h. Line indicates median, two-way ANOVA with Tukey’s multiple comparison test. F As in panel E , except in OVCAR4 cells treated for 72 h

    Article Snippet: Primary antibodies included anti- FOXM1 (Cell Signaling Technology, CST, Danvers, MA, USA) (CST #5436, 1:1,000), p-FOXM1 (Thr600) (CST #14655, 1:1,000–1:2,000), AURKB (Abcam, Waltham, MA, USA, #2254, 1:1,000), CCNB1 (CST #4138, 1:1,000–1:2,000), CDC25B (CST #9525, 1:1,000–1:2000), PLK1 (CST #4513, 1:1,000) FOXA1 (CST #53528, 1:1,000–1:2,000)), FOXK2 (CST #12008, 1:1,000), FOXO3a (CST #12829, 1:10,000), cleaved PARP (cl-PARP) (CST #5625, 1:1,000), ubiquitin (CST #14049, 1:20,000). alpha-tubulin (CST #2144, 1:5,000), β-actin (Santa Cruz Biotechnology, Dallas, TX, USA, # 47778, 1:10,000), and Lamin B1 (CST #12586, 1:1,000).

    Techniques: Gene Expression, Western Blot, Expressing, Control, Quantitative RT-PCR, Targeted Gene Expression, Concentration Assay, Comparison

    NB-73 treatment suppresses FOXM1 protein prior to FOXM1 mRNA in CAOV3 cells. A Western blot analysis of FOXM1, FOXM1-P, and β-actin expression in CAOV3 cells treated with 2.5 μM NB-73 for the indicated time points. B RT-qPCR of FOXM1 gene expression in CAOV3 cells treated with 2.5 μM NB-73 for the indicated time points. Error bars indicate mean ± SD, unpaired t-test. C FOXM1 protein and FOXM1 mRNA from three independent experiments as described in panels A and B , plotted together. Error bars indicate mean ± SD, two-way ANOVA with Dunnett’s multiple comparisons test

    Journal: Journal of Ovarian Research

    Article Title: NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells

    doi: 10.1186/s13048-024-01421-4

    Figure Lengend Snippet: NB-73 treatment suppresses FOXM1 protein prior to FOXM1 mRNA in CAOV3 cells. A Western blot analysis of FOXM1, FOXM1-P, and β-actin expression in CAOV3 cells treated with 2.5 μM NB-73 for the indicated time points. B RT-qPCR of FOXM1 gene expression in CAOV3 cells treated with 2.5 μM NB-73 for the indicated time points. Error bars indicate mean ± SD, unpaired t-test. C FOXM1 protein and FOXM1 mRNA from three independent experiments as described in panels A and B , plotted together. Error bars indicate mean ± SD, two-way ANOVA with Dunnett’s multiple comparisons test

    Article Snippet: Primary antibodies included anti- FOXM1 (Cell Signaling Technology, CST, Danvers, MA, USA) (CST #5436, 1:1,000), p-FOXM1 (Thr600) (CST #14655, 1:1,000–1:2,000), AURKB (Abcam, Waltham, MA, USA, #2254, 1:1,000), CCNB1 (CST #4138, 1:1,000–1:2,000), CDC25B (CST #9525, 1:1,000–1:2000), PLK1 (CST #4513, 1:1,000) FOXA1 (CST #53528, 1:1,000–1:2,000)), FOXK2 (CST #12008, 1:1,000), FOXO3a (CST #12829, 1:10,000), cleaved PARP (cl-PARP) (CST #5625, 1:1,000), ubiquitin (CST #14049, 1:20,000). alpha-tubulin (CST #2144, 1:5,000), β-actin (Santa Cruz Biotechnology, Dallas, TX, USA, # 47778, 1:10,000), and Lamin B1 (CST #12586, 1:1,000).

    Techniques: Western Blot, Expressing, Quantitative RT-PCR, Gene Expression

    NB compound treatment mediated FOXM1 suppression in HGSOC cells is rescued by MG132 co-treatment. A Western blot analysis of FOXM1 and total ubiquitin expression in OVCAR4 cells treated with the indicated compounds for 24 h. Protein quantification is provided below each protein band, and protein expression is normalized to DMSO control (lane 1). Ponceau S staining shows total protein loading. Protein levels were quantified using Fiji software . B As in panel A , except in COV318 cells treated for 24 h

    Journal: Journal of Ovarian Research

    Article Title: NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells

    doi: 10.1186/s13048-024-01421-4

    Figure Lengend Snippet: NB compound treatment mediated FOXM1 suppression in HGSOC cells is rescued by MG132 co-treatment. A Western blot analysis of FOXM1 and total ubiquitin expression in OVCAR4 cells treated with the indicated compounds for 24 h. Protein quantification is provided below each protein band, and protein expression is normalized to DMSO control (lane 1). Ponceau S staining shows total protein loading. Protein levels were quantified using Fiji software . B As in panel A , except in COV318 cells treated for 24 h

    Article Snippet: Primary antibodies included anti- FOXM1 (Cell Signaling Technology, CST, Danvers, MA, USA) (CST #5436, 1:1,000), p-FOXM1 (Thr600) (CST #14655, 1:1,000–1:2,000), AURKB (Abcam, Waltham, MA, USA, #2254, 1:1,000), CCNB1 (CST #4138, 1:1,000–1:2,000), CDC25B (CST #9525, 1:1,000–1:2000), PLK1 (CST #4513, 1:1,000) FOXA1 (CST #53528, 1:1,000–1:2,000)), FOXK2 (CST #12008, 1:1,000), FOXO3a (CST #12829, 1:10,000), cleaved PARP (cl-PARP) (CST #5625, 1:1,000), ubiquitin (CST #14049, 1:20,000). alpha-tubulin (CST #2144, 1:5,000), β-actin (Santa Cruz Biotechnology, Dallas, TX, USA, # 47778, 1:10,000), and Lamin B1 (CST #12586, 1:1,000).

    Techniques: Western Blot, Ubiquitin Proteomics, Expressing, Control, Staining, Software

    NB compound treatment mediated FOXM1 suppression in CAOV3 cells after drug washout. A Experimental schematic, created with BioRender. B-D Western blot analysis of FOXM1, FOXM1-P, CCNB1, and β-actin expression in CAOV3 cells treated as indicated in panel A , for B 24 h, C 48 h, and D 72 h post-treatment. E CyQuant cell viability assay data for CAOV3 cells treated with NB-73. The three curves compare data from no washout (72 h), 6 h drug exposure then washout (6 h), and 3 h drug exposure then washout (3 h). IC50 values for each condition are indicated in brackets. Error bars indicate mean ± SD, non-linear regression curve. F As in E , except for NB-115 treatment

    Journal: Journal of Ovarian Research

    Article Title: NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells

    doi: 10.1186/s13048-024-01421-4

    Figure Lengend Snippet: NB compound treatment mediated FOXM1 suppression in CAOV3 cells after drug washout. A Experimental schematic, created with BioRender. B-D Western blot analysis of FOXM1, FOXM1-P, CCNB1, and β-actin expression in CAOV3 cells treated as indicated in panel A , for B 24 h, C 48 h, and D 72 h post-treatment. E CyQuant cell viability assay data for CAOV3 cells treated with NB-73. The three curves compare data from no washout (72 h), 6 h drug exposure then washout (6 h), and 3 h drug exposure then washout (3 h). IC50 values for each condition are indicated in brackets. Error bars indicate mean ± SD, non-linear regression curve. F As in E , except for NB-115 treatment

    Article Snippet: Primary antibodies included anti- FOXM1 (Cell Signaling Technology, CST, Danvers, MA, USA) (CST #5436, 1:1,000), p-FOXM1 (Thr600) (CST #14655, 1:1,000–1:2,000), AURKB (Abcam, Waltham, MA, USA, #2254, 1:1,000), CCNB1 (CST #4138, 1:1,000–1:2,000), CDC25B (CST #9525, 1:1,000–1:2000), PLK1 (CST #4513, 1:1,000) FOXA1 (CST #53528, 1:1,000–1:2,000)), FOXK2 (CST #12008, 1:1,000), FOXO3a (CST #12829, 1:10,000), cleaved PARP (cl-PARP) (CST #5625, 1:1,000), ubiquitin (CST #14049, 1:20,000). alpha-tubulin (CST #2144, 1:5,000), β-actin (Santa Cruz Biotechnology, Dallas, TX, USA, # 47778, 1:10,000), and Lamin B1 (CST #12586, 1:1,000).

    Techniques: Western Blot, Expressing, CyQUANT Assay, Viability Assay

    NB compound treatment mediated FOXM1 suppression is independent of apoptosis. A Western blot analysis of FOXM1, FOXM1-P, cl-PARP, and β-actin expression in CAOV3 cells treated with the indicated compounds for 48 h. Numerical values below the images indicate protein expression normalized by β-actin and red numbers indicate reduced expression relative to DMSO control. B Quantified western blot data from panel A ; data from three biological replicates are plotted. Error bars indicate mean ± SD. C Western blot analysis of CCNB1, PLK1, AURKB, and CDC25B expression in CAOV3 cells treated with the indicated compounds for 48 h. D Quantified western blot data from panel C ; data from three biological replicates are plotted. Error bars indicate mean ± SD

    Journal: Journal of Ovarian Research

    Article Title: NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells

    doi: 10.1186/s13048-024-01421-4

    Figure Lengend Snippet: NB compound treatment mediated FOXM1 suppression is independent of apoptosis. A Western blot analysis of FOXM1, FOXM1-P, cl-PARP, and β-actin expression in CAOV3 cells treated with the indicated compounds for 48 h. Numerical values below the images indicate protein expression normalized by β-actin and red numbers indicate reduced expression relative to DMSO control. B Quantified western blot data from panel A ; data from three biological replicates are plotted. Error bars indicate mean ± SD. C Western blot analysis of CCNB1, PLK1, AURKB, and CDC25B expression in CAOV3 cells treated with the indicated compounds for 48 h. D Quantified western blot data from panel C ; data from three biological replicates are plotted. Error bars indicate mean ± SD

    Article Snippet: Primary antibodies included anti- FOXM1 (Cell Signaling Technology, CST, Danvers, MA, USA) (CST #5436, 1:1,000), p-FOXM1 (Thr600) (CST #14655, 1:1,000–1:2,000), AURKB (Abcam, Waltham, MA, USA, #2254, 1:1,000), CCNB1 (CST #4138, 1:1,000–1:2,000), CDC25B (CST #9525, 1:1,000–1:2000), PLK1 (CST #4513, 1:1,000) FOXA1 (CST #53528, 1:1,000–1:2,000)), FOXK2 (CST #12008, 1:1,000), FOXO3a (CST #12829, 1:10,000), cleaved PARP (cl-PARP) (CST #5625, 1:1,000), ubiquitin (CST #14049, 1:20,000). alpha-tubulin (CST #2144, 1:5,000), β-actin (Santa Cruz Biotechnology, Dallas, TX, USA, # 47778, 1:10,000), and Lamin B1 (CST #12586, 1:1,000).

    Techniques: Western Blot, Expressing, Control